We are live on ! Find out more
Daniel Devine & Co

Daniel Devine & Co Portfolio holdings

AUM $125M Turnover 9.62%
1-Year Est. Return 14.12%
This Fund
S&P 500
This Quarter Est. Return
+3.43%
1 Year Est. Return
+14.12%
3 Year Est. Return
+34.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$125M
AUM Growth
+$1.99M
Cap. Flow
-$1.63M
Cap. Flow %
-1.31%
Top 10 Hldgs %
65.84%
Holding
52
New
1
Increased
13
Reduced
13
Closed
4
Avg Time Held
2.7 years
Top 10 Avg Time Held
2.5 years
Top 20 Avg Time Held
2.3 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 56.55%
2 Healthcare 11.52%
3 Financials 7.87%
4 Technology 7.08%
5 Industrials 4.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
VOO icon
26
Vanguard S&P 500 ETF
VOO
$1.02T
$1.27M 1.02%
5,090
+3,575
+236% +$887K
2018 Q1
1 quarter
RDS.B
27
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
$1.26M 1.01%
17,325
-4,900
-22% -$353K
2014 Q4
14 quarters
BX icon
28
Blackstone
BX
$94.3B
$1.21M 0.97%
37,670
– –
2014 Q4
14 quarters
CNBKA
29
DELISTED
Century Bancorp Inc/Mass
CNBKA
$862K 0.69%
11,284
– –
2014 Q4
14 quarters
ASH icon
30
Ashland
ASH
$3.34B
$856K 0.68%
10,945
+200
+2% +$14.9K
2014 Q4
14 quarters
VWO icon
31
Vanguard FTSE Emerging Markets ETF
VWO
$117B
$838K 0.67%
19,850
+1,500
+8% +$67.7K
2014 Q4
14 quarters
APD icon
32
Air Products & Chemicals
APD
$69.7B
$820K 0.66%
5,263
– –
2014 Q4
14 quarters
EXPD icon
33
Expeditors International
EXPD
$26.6B
$793K 0.63%
10,845
+50
+0.5% +$3.49K
2014 Q4
14 quarters
XBI icon
34
State Street SPDR S&P Biotech ETF
XBI
$10.6B
$704K 0.56%
7,400
+1,100
+17% +$101K
2018 Q1
1 quarter
NTG
35
DELISTED
Tortoise Midstream Energy Fund, Inc. Common Stock
NTG
$555K 0.44%
3,250
– –
2014 Q4
14 quarters
AZN icon
36
AstraZeneca
AZN
$285B
$506K 0.4%
7,200
-11,500
-61% -$827K
2015 Q1
13 quarters
MA icon
37
Mastercard
MA
$564B
$479K 0.38%
2,435
– –
2016 Q3
7 quarters
CSX icon
38
CSX Corp
CSX
$94B
$412K 0.33%
19,392
– –
2016 Q4
6 quarters
XLE icon
39
State Street Energy Select Sector SPDR ETF
XLE
$43.9B
$404K 0.32%
10,650
– –
2014 Q4
14 quarters
ABT icon
40
Abbott
ABT
$189B
$338K 0.27%
5,535
– –
2014 Q4
14 quarters
IOO icon
41
iShares Global 100 ETF
IOO
$9.01B
$296K 0.24%
6,450
-2,400
-27% -$112K
2017 Q3
3 quarters
PG icon
42
Procter & Gamble
PG
$376B
$276K 0.22%
3,542
– –
2014 Q4
14 quarters
XLI icon
43
State Street Industrial Select Sector SPDR ETF
XLI
$31.7B
$261K 0.21%
3,645
– –
2014 Q4
14 quarters
OIH icon
44
VanEck Oil Services ETF
OIH
$1.85B
$248K 0.2%
473
– –
2014 Q4
14 quarters
MO icon
45
Altria Group
MO
$128B
$244K 0.2%
4,300
-4,300
-50% -$248K
2014 Q4
14 quarters
BKNG icon
46
Booking.com
BKNG
$117B
– –
-2,500
Closed -$208K –
HBI icon
47
DELISTED
Hanesbrands
HBI
– –
-44,570
Closed -$821K –
INTC icon
48
Intel
INTC
$322B
– –
-4,050
Closed -$211K –
TGT icon
49
Target
TGT
$70.1B
– –
-19,210
Closed -$1.33M –

Similar funds

Daniel Devine & Co's Q2 2018 Portfolio in Review

As of Q2 2018, Daniel Devine & Co held 52 positions worth $125M, up 1.6% from $123M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Daniel Devine & Co's Q2 2018 filing shows 1 new, 13 increased, 13 reduced and 4 closed positions. Its largest new stake was Walmart Inc: 60,075 shares worth $1.72M. The largest sale was Target, an estimated $1.33M.

By sector, the portfolio is most concentrated in Miscellaneous at 57% of assets, up from 54% a quarter earlier, followed by Healthcare and Financials.

  • Daniel Devine & Co's largest Q2 2018 buy was Walmart Inc: 60,075 shares worth $1.72M.
  • Daniel Devine & Co added most to Vanguard S&P 500 ETF in Q2 2018, an estimated $887K increase.
  • Daniel Devine & Co's biggest Q2 2018 reduction was AstraZeneca, cutting an estimated $827K.
  • Daniel Devine & Co fully exited Target in Q2 2018, selling an estimated $1.33M.
  • Daniel Devine & Co's ten largest holdings make up 66% of its $125M portfolio in Q2 2018.
  • Daniel Devine & Co opened 1 new position and closed 4 in Q2 2018.
  • Daniel Devine & Co's portfolio value rose 1.6% quarter-over-quarter to $125M.

Based on Daniel Devine & Co's 13F filing for Q2 2018, filed 18 Jul 2018.